Summary results for AM and PM PEF (screening period and days 1–28)
| Daily PEF, l/min, mean (SD) | PBO (N=20) | FF/VI 400/25 μg (N=40) |
| AM | ||
| Screening (PBO, n=19; FF/VI 400/25 μg, n=39) | 310.4 (75.88) | 290.4 (107.59) |
| Days 1–28 (PBO, n=20; FF/VI 400/25 μg, n=40) | 295.0 (77.89) | 318.3 (97.84) |
| PM | ||
| Screening (PBO, n=17; FF/VI 400/25 μg, n=37) | 318.8 (82.84) | 308.1 (101.11) |
| Days 1–28 (PBO, n=20; FF/VI 400/25 μg, n=40) | 303.7 (79.17) | 337.0 (101.69) |
Population sizes for each day and each time point relate to the number of patients with analysable data at the given time point.
FF, fluticasone furoate; PBO, placebo; PEF, peak expiratory flow; VI, vilanterol.